VIDEO: Factors that improve outcomes in patients with DME

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

I think that the idea that long-acting insulin that's been around has been transformative to patients, it's reduced complications. We've seen that in our patients. I think the word is getting out to with regards to getting evaluations coming in early for management of DME and for diabetic retinopathy. I think patients are realizing that they can be treated for diabetic retinopathy alone, which I think is been a hard struggle to understand that patients do want to potentially have treatments for diabetic retinopathy and prevent the complications. If I was a diabetic with any level of retinopathy, I'd want to have those injections to prevent the progression disease over time. And I think from there, we're learning more about the pathogenesis through some of these new MOAs we discussed today with those new drugs that may potentially lead to incredible durability. So whenever we may need it, you and I, on this Zoom call today, we will have plenty of options available that will prevent us from going blind from these conditions.